Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024482 | 0.98 | HRH3 (0.60) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL8778568 | 0.98 | HRH3 (0.60) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL9654053 | 0.95 | HRH3 (0.54) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL7475821 | 0.95 | DRD2 (0.58) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL7788133 | 0.89 | HRH3 (0.52) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL72014 | 0.89 | KCNH2 (0.55) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL5390369 | 0.89 | HRH3 (0.69) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL10554981 | 0.89 | HRH3 (0.69) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL10558691 | 0.89 | HRH3 (0.69) | HRH3DRD2DRD4DRD3KCNH2 | |
| SCHEMBL10559291 | 0.89 | HRH3 (0.69) | HRH3DRD2DRD4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20040158076-A1 | Tyrosine derivatives | GENENTECH, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040110753-A1 | Tyrosine derivatives | GENENTECH, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030212071-A1 | Serine protease inhibitors | GENENTECH, INC. | 2003-11-13 | — | — | US | disclosed |
| US-6472393-B1 | Serine protease inhibitors | GENENTECH, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469047-B1 | NON-PROTEIN SMALL MOLECULE COMPOUNDS WHICH INHIBIT THE INTERACTION BETWEEN THE ALPHA 4 BETA 7 INTEGRIN AND ITS LIGANDS MADCAM AND/OR VCAM. THESE COMPOUNDS ARE USEFUL FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS ARTHRITIS | GENENTECH, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1214292-A1 | TYROSINE DERIVATIVES | Genentech, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1144373-A3 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1144373-A2 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001021584-A1 | TYROSINE DERIVATIVES | GENENTECH, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000041531-A2 | SERINE PROTEASE INHIBITORS | GENENTECH, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212071-A1 | Serine protease inhibitors | SERPINE1, SPINT2, TFPI | HRH3 1634/4885DRD2 4772/4885DRD4 4822/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | HRH3 3812/4885DRD2 4826/4885DRD4 4821/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HRH3 205/4885DRD2 3294/4885DRD4 3477/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | HRH3 2765/4885DRD2 4872/4885DRD4 4880/4885 |
| US-20040110753-A1 | Tyrosine derivatives | VCAM1, ICAM1, ITGB4 | HRH3 1491/4885DRD2 2004/4885DRD4 702/4885 |
| US-20040158076-A1 | Tyrosine derivatives | VCAM1, ICAM1, ITGB4 | HRH3 1491/4885DRD2 2004/4885DRD4 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.